Latest News

Latest News

News from the World Hepatitis Alliance

WHA in official relations with WHO: What does this mean for you?

28 Feb 2015 Bridie Taylor

Fundamental to our ability to influence global hepatitis policy and bring about real change in the world of hepatitis is our relationship with the...

Need some inspiration for action? : Initiatives from WHA members

28 Feb 2015 Bridie Taylor

Together our voices are stronger and united we can tackle this global killer! The World Hepatitis Alliance is fortunate enough to be made up of...

Assisting WHO in the development of a global strategy

31 Jan 2015 Bridie Taylor

World Health Organization Member States have urged WHO to develop a comprehensive global strategy on hepatitis. To assist in the development of this...

World Hepatitis Alliance’s ever-growing membership base

31 Jan 2015 Bridie Taylor

Central to the success of the World Hepatitis Alliance are our member groups around the world. To stimulate political interest in and action on...

Joining expert committees to promote harm reduction

31 Jan 2015 Bridie Taylor

Harm reduction policies are proven to save lives. Globally, as many as 67% of People Who Inject Drugs (PWIDs) have hepatitis C and an additional 8.4...

Promoting screening among high risk communities with new multi-lingual tool

31 Jan 2015 Bridie Taylor

In Europe, migrant populations are disproportionally affected by hepatitis B and C. Crucial to reducing the burden is improving screening among these...

Supporting the development of national action plans in South America

31 Jan 2015 Bridie Taylor

Government commitment to comprehensive national action plans is key to addressing the burden of viral hepatitis. To support the development of...

Exploring new treatment developments and innovative ways to finance healthcare

31 Jan 2015 Bridie Taylor

New therapeutic developments are revolutionising the way hepatitis is treated. But with a global lack of funding, how can these pioneering new drugs...

Pages

News from infohep

Scotland’s reduction in new HCV infections due to harm reduction, not treatment

12 Jun 2018 Keith Alcorn
The reduction in new hepatitis C virus (HCV) infections that has taken place in Scotland since 2008 is most likely due to increased provision of...

Harm reduction measures for HCV prevention and treatment lacking in Europe's prisons, survey finds

31 May 2018 Keith Alcorn
Harm reduction measures for the prevention and treatment of hepatitis C in prisoners are still lacking in the majority of European countries and the...

Access to testing and treatment for hepatitis C in European prisons must improve

30 May 2018 Keith Alcorn
Lack of access to hepatitis C treatment and prevention in European prisons is a public health emergency and risks breaching international agreements...

Georgia: 98% cured of hepatitis C

23 May 2018 Keith Alcorn
Georgia is making strong progress towards eliminating hepatitis C but will need triple the number of people starting treatment if it is to reach its...

T cell immunotherapy shows promise for treating liver cancer

22 May 2018 Liz Highleyman
Personalised immunotherapy reduces the risk of liver cancer recurrence and may lead to tumour regression, according to a pair of studies presented at...

Do fatigue and quality of life improve after hepatitis C is cured?

15 May 2018 Keith Alcorn
Patient-reported outcomes such as fatigue, vitality and mental health improve substantially in the two years following hepatitis C cure for people...

Does portal hypertension always improve after hepatitis C cure?

10 May 2018 Keith Alcorn
Although portal hypertension improves in the majority of people with hepatitis C and cirrhosis after hepatitis C is cured, not all people experience...

Combining hepatitis C therapy and buprenorphine leads to good outcomes for people who inject drugs

8 May 2018 Liz Highleyman
Offering hepatitis C treatment and opioid substitution therapy with buprenorphine at the same location can help increase adherence and reduce harms...

Switching to TAF improves safety in people with hepatitis B with kidney and bone risk factors

4 May 2018 Liz Highleyman
People with risk factors for tenofovir toxicity who switched from tenofovir disoproxil fumarate (TDF; Viread) to the new tenofovir alafenamide (TAF;...

Fewer non-liver cancers in people treated with DAAs compared to the interferon era

2 May 2018 Keith Alcorn
The risk of non-liver cancer is lower in people treated with direct-acting antivirals (DAAs) than in those treated with interferon and is probably an...